Imugene, a leading biopharmaceutical company, has announced the opening of enrollment for a pivotal expansion study targeting bile tract cancer (cholangiocarcinoma) patients. This new phase of the study, known as the MAST trial, comes on the heels of the successful completion of the fifth high-dose cohort in the intratumoral arm of the VAXINIA monotherapy dose escalation study.
The VAXINIA study, which evaluates the effectiveness of the cancer-killing virus CF33-hNIS (VAXINIA), has already shown promising results in gastrointestinal cancers. Notably, the trial has seen remarkable outcomes, including one patient with cholangiocarcinoma achieving a complete response and another maintaining stable disease.
Imugene’s CEO, Leslie Chong, has expressed her excitement about the new phase of the study, stating, ‘The expansion trial aims to enrol 10 patients and is part of our broader efforts to advance our innovative oncological treatments. Previous phases have demonstrated significant positive responses, especially in gastrointestinal cancers, further underscoring the potential of VAXINIA.’
In addition to the expansion study, Imugene will present VAXINIA at the 2024 Cholangiocarcinoma Foundation Annual Conference. This event will provide an opportunity for the company to gather further support for its cutting-edge therapies, which have so far shown no safety concerns across various cancer types, including thymic carcinoma and triple-negative breast cancer.
Imugene’s commitment to advancing its innovative oncological treatments, particularly in the challenging field of bile tract cancer, underscores the company’s dedication to improving the lives of patients facing this devastating disease. The MAST trial and the continued development of VAXINIA hold the promise of new hope for those affected by cholangiocarcinoma.
}
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Imugene Expands Bile Tract Cancer Study with Promising VAXINIA Results.